carvedilol has been researched along with Insulin Resistance in 21 studies
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 9.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "In patients after myocardial infarction, carvedilol added to background therapy improved insulin resistance and lipid profile." | 9.12 | After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. ( Altuntas, Y; Basat, O; Oztekin, E; Seber, S; Ucak, S, 2006) |
| "Additional treatment with carvedilol is neutral with regard to influence the insulin sensitivity in patients with mild to moderate CHF." | 9.10 | Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. ( Andreasen, F; Gøtzsche, O; Refsgaard, J; Thomsen, C, 2002) |
| "To compare the effects of a 3 months' antihypertensive treatment with carvedilol, a non-selective beta-adrenoceptor blocker with alpha 1-blocking properties, with the beta 1-selective receptor blocker metoprolol on insulin sensitivity in non-diabetic hypertensive patients." | 9.08 | Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. ( Agrawal, B; Augustin, HJ; Dietze, GJ; Jacob, S; Rett, K; Wicklmayr, M, 1996) |
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 7.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 7.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 7.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 6.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Carvedilol treatment reversed thyroxin induced hypertriglyceridemia, whereas propranolol treatment had no effect." | 5.34 | Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism--an experimental study. ( Bhatt, P; Goyal, R; Makwana, D; Santani, D, 2007) |
| "This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes." | 5.14 | Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. ( Christiansen, B; Dominguez, H; Hermann, TS; Kveiborg, B; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2010) |
| "Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia." | 5.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| "In patients after myocardial infarction, carvedilol added to background therapy improved insulin resistance and lipid profile." | 5.12 | After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. ( Altuntas, Y; Basat, O; Oztekin, E; Seber, S; Ucak, S, 2006) |
| "In patients with diabetes and hypertension not taking insulin sensitizers, the use of metoprolol tartrate resulted in a worsening of insulin resistance, an effect not seen with carvedilol." | 5.12 | Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2007) |
| "Additional treatment with carvedilol is neutral with regard to influence the insulin sensitivity in patients with mild to moderate CHF." | 5.10 | Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. ( Andreasen, F; Gøtzsche, O; Refsgaard, J; Thomsen, C, 2002) |
| "To compare the effects of a 3 months' antihypertensive treatment with carvedilol, a non-selective beta-adrenoceptor blocker with alpha 1-blocking properties, with the beta 1-selective receptor blocker metoprolol on insulin sensitivity in non-diabetic hypertensive patients." | 5.08 | Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. ( Agrawal, B; Augustin, HJ; Dietze, GJ; Jacob, S; Rett, K; Wicklmayr, M, 1996) |
| "We aimed to investigate the acute and chronic effects of carvedilol on insulin resistance in high-fructose, high-fat diet (HFrHFD) - fed mice and the implication of the β-arrestin2 pathway." | 4.12 | Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF; Mohamed, SG; Rezk, AM, 2022) |
| "Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders." | 3.91 | Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice. ( Baker, S; Dang, TB; Doan, KV; Kim, KW; Le Tran, T; Nguyen, LV; Nguyen, PH; Nguyen, T; Nguyen, TH; Pham, TVH; Ta, QV; Yang, DJ, 2019) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 3.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 3.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 2.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Carvedilol was adiministered for 4 weeks starting at week 13." | 1.56 | Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling. ( Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2020) |
| "Losartan treatment could be an effective tool to restore normal vascular reactivity in the renal circulation of the fructose-fed rat." | 1.38 | The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats. ( Abdulla, MH; Abdullah, NA; Johns, EJ; Sattar, MA, 2012) |
| "Insulin resistance is prevalent in heart failure (HF) patients, and beta2 adrenergic receptors (beta2-AR) are involved in glucose homeostasis." | 1.35 | The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. ( Detry, MA; Johnson, MR; Moran, JJ; Sweitzer, NK; Vardeny, O, 2008) |
| "Carvedilol treatment reversed thyroxin induced hypertriglyceridemia, whereas propranolol treatment had no effect." | 1.34 | Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism--an experimental study. ( Bhatt, P; Goyal, R; Makwana, D; Santani, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, HMS | 1 |
| Mohamed, SG | 1 |
| Ibrahim, WS | 2 |
| Rezk, AM | 1 |
| Mahmoud, AAA | 2 |
| Mahmoud, MF | 2 |
| Ibrahim, IAAE | 2 |
| Nguyen, LV | 1 |
| Ta, QV | 1 |
| Dang, TB | 1 |
| Nguyen, PH | 1 |
| Nguyen, T | 1 |
| Pham, TVH | 1 |
| Nguyen, TH | 1 |
| Baker, S | 1 |
| Le Tran, T | 1 |
| Yang, DJ | 1 |
| Kim, KW | 1 |
| Doan, KV | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Oh, PC | 1 |
| Kang, WC | 1 |
| Moon, J | 1 |
| Park, YM | 1 |
| Kim, S | 1 |
| Kim, MG | 1 |
| Lee, K | 1 |
| Ahn, T | 1 |
| Shin, EK | 1 |
| Stafylas, PC | 1 |
| Sarafidis, PA | 1 |
| Vardeny, O | 1 |
| Detry, MA | 1 |
| Moran, JJ | 1 |
| Johnson, MR | 1 |
| Sweitzer, NK | 1 |
| Phillips, RA | 2 |
| Fonseca, V | 2 |
| Katholi, RE | 2 |
| McGill, JB | 2 |
| Messerli, FH | 2 |
| Bell, DS | 2 |
| Raskin, P | 2 |
| Wright, JT | 2 |
| Iyengar, M | 1 |
| Anderson, KM | 2 |
| Lukas, MA | 2 |
| Bakris, GL | 2 |
| Kveiborg, B | 2 |
| Hermann, TS | 1 |
| Major-Pedersen, A | 1 |
| Christiansen, B | 2 |
| Rask-Madsen, C | 1 |
| Raunsø, J | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 2 |
| Dominguez, H | 1 |
| Conde, SV | 1 |
| Nunes da Silva, T | 1 |
| Gonzalez, C | 1 |
| Mota Carmo, M | 1 |
| Monteiro, EC | 1 |
| Guarino, MP | 1 |
| Abdulla, MH | 1 |
| Sattar, MA | 1 |
| Abdullah, NA | 1 |
| Johns, EJ | 1 |
| Fragasso, G | 1 |
| Spoladore, R | 1 |
| Maranta, F | 1 |
| Corti, A | 1 |
| Lattuada, G | 1 |
| Colombo, B | 1 |
| Locatelli, M | 1 |
| Salerno, A | 1 |
| Calori, G | 1 |
| Briceno, L | 1 |
| Alfieri, AB | 1 |
| Perseghin, G | 1 |
| Margonato, A | 1 |
| Refsgaard, J | 1 |
| Thomsen, C | 1 |
| Andreasen, F | 1 |
| Gøtzsche, O | 1 |
| Hara, Y | 1 |
| Hamada, M | 1 |
| Shigematsu, Y | 1 |
| Ohtsuka, T | 1 |
| Ogimoto, A | 1 |
| Higaki, J | 1 |
| Gonzalez-Feldman, E | 1 |
| Basat, O | 1 |
| Ucak, S | 1 |
| Seber, S | 1 |
| Oztekin, E | 1 |
| Altuntas, Y | 1 |
| Major-Petersen, A | 1 |
| Waterhouse, B | 1 |
| Bhatt, P | 1 |
| Makwana, D | 1 |
| Santani, D | 1 |
| Goyal, R | 1 |
| Kovacić, D | 1 |
| Marinsek, M | 1 |
| Gobec, L | 1 |
| Lainscak, M | 1 |
| Podbregar, M | 1 |
| Jacob, S | 1 |
| Rett, K | 1 |
| Wicklmayr, M | 1 |
| Agrawal, B | 1 |
| Augustin, HJ | 1 |
| Dietze, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris[NCT02547597] | Phase 4 | 99 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [NCT00497003] | Phase 4 | 50 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carvedilol and Insulin Resistance
| Article | Year |
|---|---|
Carvedilol in hypertension treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Comorbidity; Hemodynam | 2008 |
Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus; Glucose; Humans; In | 2006 |
9 trials available for carvedilol and Insulin Resistance
| Article | Year |
|---|---|
Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angina, Stable; Atenolol; Carbazoles; Cardiotonic Agen | 2016 |
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Press | 2008 |
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Dose-Respon | 2010 |
Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
Effect of beta-blockers on insulin resistance in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardi | 2003 |
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; C-Peptide; Carbazoles; Carve | 2006 |
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Metho | 1996 |
Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Metho | 1996 |
Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Metho | 1996 |
Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Metho | 1996 |
10 other studies available for carvedilol and Insulin Resistance
| Article | Year |
|---|---|
Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway.
Topics: Animals; beta-Arrestin 2; Carvedilol; Diet, High-Fat; Dietary Carbohydrates; Diglycerides; Dyslipide | 2022 |
Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice.
Topics: Adipose Tissue, White; Administration, Oral; Adrenergic Agents; Adrenergic beta-Antagonists; Animals | 2019 |
Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.
Topics: Animals; beta-Arrestin 2; Cardiomegaly; Carvedilol; Cytokines; Diet, High-Fat; Dietary Sugars; Disea | 2020 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2008 |
Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats.
Topics: Adiposity; Adrenergic Antagonists; Animals; Body Weight; Caffeine; Carbazoles; Carvedilol; Catechola | 2012 |
The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats.
Topics: Angiotensin II; Animals; Body Weight; Carbazoles; Carvedilol; Fructose; Glucose Tolerance Test; Hemo | 2012 |
Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; Cytokines; Echocardiograp | 2013 |
Carvedilol, metoprolol, and insulin resistance.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Humans; Hypertension; In | 2005 |
Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism--an experimental study.
Topics: Adrenergic beta-Antagonists; Animals; Appetite; Blood Glucose; Blood Pressure; Body Mass Index; Body | 2007 |